🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Sjogren's Disease

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646NA1 site📍 Shanghai China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 Rare AutoImmune SElf-management Programme Development NCT06642870n/a1 site📍 Bristol University of the West of England · Tests: Non-interventional study Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: CD19- BCMA CAR-T cells B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome NCT04931160NA1 site📍 Brest University Hospital, Brest · Tests: Blood, fluid, sells and urine samples Rheumatology Diet Study NCT06339957n/a1 site📍 Orlando University of Central Florida Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases NCT06828042Phase 1, Phase 21 site📍 Beijing Peking University Third Hospital · Tests: anti-CD19 CAR T cell therapy Belimumab After Rituximab in Resistant Primary Juvenile SS NCT06410833Phase 41 site📍 Beijing Peking Union Medical College Hospital · Tests: Rituximab, Belimumab BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy Ultra-High Frequency Ultrasonography in Sjögren's Syndrome NCT06338735NA1 site📍 Pisa University of Pisa · Tests: Ultra-High Frequency Ultrasound scan of minor salivary glands Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome NCT06967038Phase 1, Phase 21 site📍 Shanghai Bangdong Gong · Tests: CAR-NK cell Laser Acupuncture on Dry Eye and Sjögren's Syndrome-related Dry Eye Symptoms (LADESJS) NCT06780293Phase 21 site📍 Taipei Taipei Veterans General Hospital, Taiwan · Tests: Laser acupuncture (LA), Numerical Rating Scale (NRS), Schirmer's test, Ocular Surface Disease Index (OSDI), EULAR … Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease NCT07404865Phase 349 sites📍 Chandler📍 Flagstaff📍 Glendale Vor Biopharma · Tests: Telitacicept, Placebo Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study NCT07544394n/a1 site📍 Kahramanmaraş Kahramanmaras Sutcu Imam University Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia NCT06392711Phase 11 site📍 Madison University of Wisconsin, Madison · Tests: Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1 Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases NCT06842316n/a1 site📍 Orléans Centre Hospitalier Régional d'Orléans · Tests: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease) Rheumatology Patient Registry and Biorepository NCT04402086n/a1 site📍 New Haven Yale University Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity NCT03003572n/a8 sites📍 Bourgoin📍 Clermont-Ferrand📍 Grenoble Centre Hospitalier Universitaire de Saint Etienne · Tests: Blood samples TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE NCT07153276Phase 41 site📍 São Paulo University of Sao Paulo General Hospital · Tests: Fractional CO2 laser (vaginal), Promestriene Vaginal Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients NCT07249060n/a1 site📍 Pamplona Hospital Universitario Araba · Tests: Immune Checkpoint Inhibitors AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. NCT06991114Phase 252 sites📍 Tuscaloosa📍 Phoenix📍 Tucson Artiva Biotherapeutics, Inc. · Tests: Allogeneic NK Cells Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden NCT07621809Phase 333 sites📍 Peoria📍 Clearwater📍 Tampa Novartis Pharmaceuticals · Tests: VAY736, Placebo Exosomes Proteomic for Sjogren's Syndrome and Dry Eye Syndrome NCT06771427n/a1 site📍 Taipei Taipei Veterans General Hospital, Taiwan · Tests: acupuncture GB20 or GB20 plus BL2, Chinese herbal tea TBDESJS A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) NCT06747949Phase 3174 sites📍 Avondale📍 Flagstaff📍 Gilbert Amgen · Tests: Dazodalibep A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body NCT07649265Phase 11 site📍 Brisbane Otsuka Pharmaceutical Development & Commercialization, Inc. · Tests: HBM7020 Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases NCT06428188Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: BCMA/CD19 CAR-T cells Maternal Autoimmune Disease Research Alliance (MADRA) Registry NCT03276923n/a1 site📍 Durham Duke University Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease NCT07843381n/a1 site📍 Beijing Peking University People's Hospital · Tests: Telitacicept 160mg, Conventional treatment Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases NCT07236801Phase 12 sites📍 Xuzhou📍 Xuzhou China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE NCT07118241Phase 27 sites📍 Sydney📍 Sydney📍 Brisbane Lubris Bio Pty Ltd · Tests: Recombinant Human Proteoglycan 4, Vehicle Control A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases NCT07712939Phase 11 site📍 Melbourne Candid Therapeutics · Tests: CND319
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy